Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

51 views

Visitors from

US 54%·

AU 32%·

IN 7%·

GB 2%·

FR 2%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

Why Omnicell (OMCL) Shares Are Plunging Today

February 05, 2026 at 11:56 AM EST

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

OMCL Cover Image

What Happened?

Shares of healthcare tech company Omnicell (NASDAQ: OMCL) fell 18.4% in the morning session after the company reported fourth-quarter earnings that fell short of Wall Street expectations and provided a disappointing forecast for the 2026 financial year.

Omnicell posted adjusted earnings of $0.40 per share, missing analyst estimates of $0.50. This figure was also down from the $0.60 per share reported in the same quarter last year. While revenue for the quarter came in at $314 million, meeting expectations, the significant profit miss concerned investors. Adding to the pressure, the company's guidance for the upcoming year also weighed on the stock. Omnicell's forecast for adjusted earnings per share and EBITDA for the 2026 financial year came in below analyst expectations, signaling potential weakness ahead.

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Omnicell? Access our full analysis report here, it’s free.

What Is The Market Telling Us

Omnicell’s shares are quite volatile and have had 16 moves greater than 5% over the last year. But moves this big are rare even for Omnicell and indicate this news significantly impacted the market’s perception of the business.

The biggest move we wrote about over the last year was 9 months ago when the stock dropped 17.5% on the news that the company reported weak first-quarter 2025 results, which featured full-year EPS and EBITDA guidance that fell short of Wall Street's estimates. On the other hand, Omnicell blew past analysts' EPS and revenue estimates. Still, this was a weaker quarter.

Omnicell is down 11% since the beginning of the year, and at $40.19 per share, it is trading 21.8% below its 52-week high of $51.39 from January 2026. Investors who bought $1,000 worth of Omnicell’s shares 5 years ago would now be looking at an investment worth $313.37.

The 1999 book Gorilla Game predicted Microsoft and Apple would dominate tech before it happened. Its thesis? Identify the platform winners early. Today, enterprise software companies embedding generative AI are becoming the new gorillas. Click here for access to our special report that reveals one profitable leader already riding this wave, it’s free.

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Symbol

Price

Change (%)

AMZN

266.32

-2.14 (-0.80%)

AAPL

308.82

+3.83 (1.26%)

AMD

467.51

+17.92 (3.99%)

BAC

51.80

+0.31 (0.60%)

GOOG

379.38

-4.09 (-1.07%)